JP2016028090A5 - - Google Patents

Download PDF

Info

Publication number
JP2016028090A5
JP2016028090A5 JP2015187057A JP2015187057A JP2016028090A5 JP 2016028090 A5 JP2016028090 A5 JP 2016028090A5 JP 2015187057 A JP2015187057 A JP 2015187057A JP 2015187057 A JP2015187057 A JP 2015187057A JP 2016028090 A5 JP2016028090 A5 JP 2016028090A5
Authority
JP
Japan
Prior art keywords
medicament according
treatment
emetic
subject
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015187057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016028090A (ja
JP6279526B2 (ja
Filing date
Publication date
Priority claimed from GBGB1004020.2A external-priority patent/GB201004020D0/en
Application filed filed Critical
Publication of JP2016028090A publication Critical patent/JP2016028090A/ja
Publication of JP2016028090A5 publication Critical patent/JP2016028090A5/ja
Application granted granted Critical
Publication of JP6279526B2 publication Critical patent/JP6279526B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015187057A 2010-03-11 2015-09-24 鎮吐薬としてのアミスルプリドの使用 Active JP6279526B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1004020.2 2010-03-11
GBGB1004020.2A GB201004020D0 (en) 2010-03-11 2010-03-11 New therapeutic use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012556586A Division JP5886213B2 (ja) 2010-03-11 2011-03-10 鎮吐薬としてのアミスルプリドの使用

Publications (3)

Publication Number Publication Date
JP2016028090A JP2016028090A (ja) 2016-02-25
JP2016028090A5 true JP2016028090A5 (enExample) 2016-07-28
JP6279526B2 JP6279526B2 (ja) 2018-02-14

Family

ID=42136792

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012556586A Active JP5886213B2 (ja) 2010-03-11 2011-03-10 鎮吐薬としてのアミスルプリドの使用
JP2015187057A Active JP6279526B2 (ja) 2010-03-11 2015-09-24 鎮吐薬としてのアミスルプリドの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012556586A Active JP5886213B2 (ja) 2010-03-11 2011-03-10 鎮吐薬としてのアミスルプリドの使用

Country Status (26)

Country Link
US (12) US9084765B2 (enExample)
EP (3) EP2796171B1 (enExample)
JP (2) JP5886213B2 (enExample)
KR (1) KR101738201B1 (enExample)
CN (1) CN102892407B (enExample)
AU (1) AU2011225898B2 (enExample)
BR (1) BR112012022746B1 (enExample)
CA (1) CA2792392C (enExample)
CY (3) CY1115485T1 (enExample)
DK (3) DK2796171T3 (enExample)
EA (1) EA030335B1 (enExample)
ES (3) ES2496099T3 (enExample)
GB (1) GB201004020D0 (enExample)
HR (3) HRP20140744T1 (enExample)
HU (1) HUE037088T2 (enExample)
IL (1) IL221746A (enExample)
LT (1) LT2796171T (enExample)
MX (3) MX2012010411A (enExample)
NO (1) NO2796171T3 (enExample)
NZ (1) NZ602279A (enExample)
PL (3) PL2544657T3 (enExample)
PT (3) PT2544657E (enExample)
RS (3) RS53466B (enExample)
SI (3) SI2796171T1 (enExample)
SM (3) SMT201800188T1 (enExample)
WO (1) WO2011110854A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
CN104435861A (zh) * 2014-12-22 2015-03-25 济南伟传信息技术有限公司 一种治疗妊娠剧吐的茶
GB201506116D0 (en) 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
US10761020B2 (en) 2015-09-02 2020-09-01 California Institute Of Technology Method and apparatus for the spectroscopic detection of low concentrations of hydrogen sulfide gas
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
MX2020005517A (es) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Formas cristalinas y metodos de produccion de las mismas.
US10369134B2 (en) 2017-12-05 2019-08-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
WO2020247603A1 (en) * 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2020247627A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
EP4175631A1 (en) 2020-07-06 2023-05-10 Acacia Pharma Ltd Therapy of post-operative nausea and vomiting
EP4496797A1 (en) 2022-03-21 2025-01-29 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2026501171A (ja) 2022-12-15 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド Glp-1アゴニスト活性を有する化合物の塩および固体形態
EP4638455A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4638440A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AU2024222719A1 (en) 2023-02-16 2025-08-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20250019389A1 (en) 2023-06-30 2025-01-16 Gasherbrum Bio, Inc. Heterocyclic agonists
TW202521528A (zh) 2023-07-13 2025-06-01 美商雅空嘉閣生物公司 化合物、組合物及方法
WO2025015269A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss
WO2026041075A1 (en) 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
US20070190145A1 (en) 2006-01-27 2007-08-16 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
WO2007096489A1 (fr) * 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) * 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
EP3090743A1 (en) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
US8138169B2 (en) * 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use

Similar Documents

Publication Publication Date Title
JP2016028090A5 (enExample)
JP2016106150A5 (enExample)
JP2016501828A5 (enExample)
JP2009525343A5 (enExample)
HRP20180436T1 (hr) Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima
JP2014040437A5 (enExample)
HRP20160361T1 (hr) Terapija u kombinaciji s antitumorskim alkaloidom
JP2013155188A5 (enExample)
JP2013151541A5 (enExample)
JP2012193216A5 (enExample)
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
JP2015522522A5 (enExample)
EP4606430A3 (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration
JP2013166781A5 (enExample)
JP2016532516A5 (enExample)
MY204827A (en) Semaglutide in medical therapy
JP2016527312A5 (ja) ヒスタミンh4受容体を介してもたらされた掻痒状態を治療するための医薬組成物
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
MX2016014695A (es) Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica.
JP2014148552A5 (enExample)
JP2019501194A5 (enExample)
WO2015009731A3 (en) Azacyclic constrained analogs of fty720
IL300144A (en) Benzazepines are combined for the treatment of Tourette syndrome
JP2016528283A5 (enExample)
JP2008539169A5 (enExample)